Lowered from $1.29 because of some delays at new support center as indicated by company. Those delays should cause NO decrease in annual EPS ($6.79) as they will simply roll forward to Q2, which will be up significantly and Q3 & Q4 will be EXPLOSIVE GROWTH IN TOP AND BOTTOM LINE as over 100 new reps hit full productivity!!! IF BOTH NS AND RHEUMATOLOGY (NS is virtually certain) takes off (already has started) then $6.79 will be way too conservative...It is based on STRONG GROWTH in NS and decent growth in Rheumatology.
Stock buybacks and their accretive impact are far too difficult to estimate (for me or ANYONE) and even the company can't know because another acquisition (like Biovectra) could come along just as they were about to buy back X million shares (simply an example). So NO it is NOT calculated in my model at all. BUT buying the full 7 million shares would amount to 13-15% accretion so simply add back up to that times inherent EPS. BUT in turn remember that accretion then goes into the DCF for ALL "out" periods in determining valuation!!!